MiddleBrook launches Moxatag, first ER amoxicillin

Texas, USA-based MiddleBrook Pharmaceuticals has launched Moxatag tablets, 775mg, the first and only Food and Drug Administration-approved  once-daily amoxicillin. The drug is cleared for the treatment of  pharyngitis/tonsillitis secondary to Streptococcus pyogenes in patients  12 years and older. The current most-commonly prescribed generic  amoxicillin treatment regimen for pharyngitis/tonsillitis which is 500mg  three times per day, according to the 2008 IMS Health National Drug  Therapeutic Index. There is no AB-rated generic for Moxatag, the company  points out.

This is the first product formulated with MiddleBrook's proprietary  PULSYS technology, which enables the pulsatile delivery, or delivery in  rapid bursts, of amoxicillin.

"Moxatag's once-daily dosing advances traditional treatment with  amoxicillin, a drug that has been trusted and relied upon for the  treatment of pharyngitis and tonsillitis for decades," said MiddleBrook  chief executive John Thievon, noting that the drug is effective and uses  a lower overall dose than conventional amoxicillin or penicillin  treatments for pharyngitis and tonsillitis.